Phase I study of oral GZ17-6.02 in patients with advanced solid tumors or lymphoma

被引：0
|
作者：
Mita, A. [1 ]
Mita, M. [1 ]
Tsai, F. [2 ]
Moore, R. P. [3 ]
Bailes, J. [3 ]
Matrana, M. [4 ]
机构：
[1] Cedars Sinai Med Ctr, Oncol, Los Angeles, CA 90048 USA
[2] Honor Hlth Res & Innovat Inst, Oncol, Scottsdale, AZ USA
[3] Genzada Pharmaceut, R&D, Hutchinson, KS USA
[4] Ochsner Canc Inst, Oncol, New Orleans, LA USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
548P
引用
收藏
页码：S609 / S610
页数：2
相关论文
共 50 条
  • [21] A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors
    Schoffski, Patrick
    Aftimos, Philippe
    Dumez, Herlinde
    Deleporte, Amelie
    De Block, Katrien
    Costermans, Jo
    Billiet, Maureen
    Meeus, Marie-Anne
    Lee, Chooi
    Schnell, David
    Goeldner, Rainer-Georg
    Awada, Ahmad
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (01) : 99 - 108
  • [22] Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumors
    Hendlisz, A.
    Voest, E. E.
    Schellens, J.
    Awada, A.
    Witteveen, P.
    Stuurman, R.
    Rasch, W.
    Hals, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
    Portnow, J.
    Frankel, P.
    Koehler, S.
    Twardowski, P.
    Shibata, S.
    Martel, C.
    Morgan, R.
    Cristea, M.
    Chow, W.
    Lim, D.
    Chung, V.
    Reckamp, K.
    Leong, L.
    Synold, T. W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 505 - 514
  • [24] A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors
    Haddad, Tufia
    Qin, Rui
    Lupu, Ruth
    Satele, Daniel
    Eadens, Matthew
    Goetz, Matthew P.
    Erlichman, Charles
    Molina, Julian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1221 - 1227
  • [25] A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
    Kato, Shumei
    Adashek, Jacob J.
    Subbiah, Vivek
    Fu, Siqing
    Sun, Mianen
    Nguyen, Ly
    Brown, Elsa J.
    Yap, Timothy A.
    Karp, Daniel D.
    Piha-Paul, Sarina A.
    Hong, David S.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 99 - 105
  • [26] A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors
    Tufia Haddad
    Rui Qin
    Ruth Lupu
    Daniel Satele
    Matthew Eadens
    Matthew P. Goetz
    Charles Erlichman
    Julian Molina
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 1221 - 1227
  • [27] A phase I study of the ceramide nanoliposome in patients with advanced solid tumors
    Ciner, Aaron
    Gourdin, Theodore
    Davidson, Jeff
    Parette, Mylisa
    Walker, Susan J.
    Fox, Todd E.
    Jiang, Yixing
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (01) : 23 - 29
  • [28] Phase I study of docetaxel and ifosfamide in patients with advanced solid tumors
    Pronk, L
    Shrijvers, D
    LocciTonelli, D
    Verweij, J
    VanOosterom, AT
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 961 - 961
  • [29] A phase I study of resminostat in Japanese patients with advanced solid tumors
    Satoru Kitazono
    Yutaka Fujiwara
    Shinji Nakamichi
    Hidenori Mizugaki
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Eri Inukai
    Osamu Nakamura
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1155 - 1161
  • [30] Phase I study of olaratumab in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Ma, Yan
    Dontabhaktuni, Aruna
    Nippgen, Cornelia
    Nippgen, Johannes
    Ohtsu, Atsushi
    CANCER SCIENCE, 2014, 105 (07) : 862 - 869
12345